Adagio Medical Completes Enrollment for FULCRUM-VT Pivotal Clinical Trial Evaluating Cryoablation for Ventricular Tachycardia

Adagio Medical has completed enrollment for the FULCRUM-VT pivotal clinical trial evaluating its ultra-low temperature cryoablation technology for ventricular tachycardia treatment. The study, which has enrolled 208 patients across 20 centers in the US and Canada, will support a pre-market approval application for the vCLAS System. The technology has been granted Breakthrough Device Designation by the FDA and aims to address the limitations of current VT ablation technologies.